The UK has unveiled £34.5 million ($42.8 million) in funding for four hubs dedicated to the development of vaccines for diseases with epidemic potential in low- and middle-income countries (LMICs).
The company finalizes a deal to establish its first manufacturing facility in Africa, which will have the capacity to produce 500 million vaccine doses per year.
mRNA pioneer Moderna has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish an mRNA manufacturing facility in the country.
Marken, the clinical trial logistics subsidiary of UPS Healthcare, is adding significant capacity to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials.
